Track topics on Twitter Track topics that are important to you
UPDATED // An FDA panel recommended liraglutide for the additional indication of reducing the risk for major adverse cardiovascular events in adults with type 2 diabetes and high cardiovascular risk.
Medscape Medical News
Original Article: FDA Panel Backs Liraglutide to Reduce CV Risk FactorsNEXT ARTICLE
Cardiovascular disease (CVD)
Acute Coronary Syndromes (ACS) Blood Cardiovascular Dialysis Hypertension Stent Stroke Vascular Cardiovascular disease (CVD) includes all the diseases of the heart and circulation including coronary heart disease (angina...